Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Etsy

Netflix

The S&P 500's worst performers have all lost more than 30% this year.

Moderna, Netflix, and Etsy Are the S&P 500's Worst Performing Stocks This Year

Spikevax sales may not be able to carry the stock upward any further.

What's Next For Moderna Stock?

AstraZeneca

Vertex Pharmaceuticals

All of them have tremendous growth prospects.

3 Unstoppable Biotech Stocks to Buy Right Now

The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.

Moderna Is Betting on a New Way to Fight Cancer

It's important to look at the big picture.

The Worst Mistake Moderna Investors Can Make in 2022

Shares of Moderna Inc. MRNA, -2.51% slumped 2.3% toward an eight-month low in morning trading Friday, and have tumbled 26.5% amid a six-day losing streak, enough for formerly bearish BofA Securities analyst Geoff Meacham to say investors should stop selling the biotechnology company. Meacham raised his rating to neutral from underperform, and lifted his stock price target to $180 from $135.

Moderna's stock has tumbled enough for a long-time bear to say stop selling

Moderna was last year's third best-performing stock in the S&P—it's now this year's worst.

Moderna Stock Crash Intensifies: Losses Top $130 Billion After Scientists Find Covid Boosters Aren't Halting Omicron Infections

BioNTech SE

Novavax

Ocugen, Inc.

Several factors are dragging down these vaccine stocks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

The huge new CDC dataset backs up what other studies have found, that Moderna is edging out Pfizer and J&J is offering less protection against COVID.

One chart shows people vaccinated with Moderna had the best protection against COVID in 2021

Allogene Therapeutics Inc

Prometheus Biosciences

Theseus Pharmaceuticals

UnitedHealth Group

Check out these health care firms taking center stage in the stock market now.

Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch

Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.

Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?

Moderna's chief executive officer Stephane Bancel said the company hopes to have a combined flu and COVID vaccine ready for 2023, but virus experts speaking on a panel Monday poured cold water on the possibly of the pandemic shifting to an endemic phase this year.

Moderna aims for COVID/flu booster in 2023, but Fauci and other virus experts warn of challenges to come this year

Moderna is looking to expand the use of mRNA drug technology to other vaccines. So far, investors haven't been impressed by progress on a flu shot.

Moderna Targets Fall 2023 for Covid-Flu Combo Vaccine

It's important to look at vaccine sales prospects -- and potential future products.

Is Moderna Stock Too Expensive in 2022?

Regeneron Pharmaceuticals

Both companies are involved in the fight against COVID-19.

2 Top Biotech Stocks to Buy and Hold for 10 Years

Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity. Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.

Moderna: High Upside Potential At Current Prices

When Will Moderna Stock Be a Screaming Buy?

Almost all adults have been infected by the Epstein-Barr virus, which scientists believe is the likely cause of multiple sclerosis, a potentially disabling neurological condition.

Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes Multiple Sclerosis

COVID-19 vaccine stocks are all retreating sharply for a second day running on Friday. The U.S. Supreme Court on Thursday ruled against President Joe Biden's quest to make it mandatory for large businesses employing over 100 people to have their staff vaccinated and undergo weekly testing.

Why Moderna, Novavax And Other Vaccine Stocks Are Extending Losses Today

The vaccine mandate was aimed at private companies with more than 100 employees. The ruling upheld a mandate for healthcare workers.

Moderna and Novavax extend losses after Supreme Court strikes down Biden's vaccine mandate for private employers

Shares of the biotech stocks are getting hit hard after the ruling blocked President Biden's mandate.

Moderna, Novavax, and Other Vaccine Stocks Get Whacked by Supreme Court's Vaccine Decision

Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back following 2021 strength, with investors continuing to weigh sector outlook going into 2022. The US Supreme Court today blocked President Biden's workplace vaccine-or-test mandate for larger employers.

What's Going On With Moderna, BioNTech And Novavax Stock Today

Apple

Amazon

Home Depot

Spotify

Target

Here are seven hot stocks that could provide investors with the long-term returns worth considering if their prices go down this year. The post 7 Hot Stocks to Pounce on if Their Prices Drop appeared first on InvestorPlace.

7 Hot Stocks to Pounce on if Their Prices Drop

Moderna Inc. ( MRNA , Financial) revealed on Wednesday that it will not release data from its Covid-19 vaccine trial in children ages two to five until March.

Moderna Plans March Release of Children's Vaccine Trial Data

If data are promising, Moderna says it will proceed with regulatory filings for the vaccine for kids aged 2 to 5.

News for Moderna Stock (MRNA)